@article{ATM8036,
author = {Marco Ruella and Bruce Levine},
title = {Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma},
journal = {Annals of Translational Medicine},
volume = {4},
number = {1},
year = {2015},
keywords = {},
abstract = {In a recent issue of the journal Science Translational Medicine, Dr. Johnson and our colleagues at the University of Pennsylvania reported on the rational development and characterization of humanized anti-epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR) T cells for glioblastoma (1). In this article, the authors describe the successful preclinical validation of a highly-selective humanized anti-EGFRvIII CAR T cell product that is currently employed in a phase I trial open at the University of Pennsylvania and the University of California San Francisco for patients with glioblastoma (NCT02209376).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/8036}
}